Abstract
Introduction
Many breast cancer patients remove their contralateral breast unaffected by cancer, commonly referred to as contralateral prophylactic mastectomy (CPM). CPM has been extensively studied and does not improve survival in patients without deleterious genetic mutation or lobular histology. Despite these limited indications, CPM rates have increased recently. We observed CPM trends in our county safety-net hospital.
Methods
We performed a retrospective review of women treated for breast cancer who underwent bilateral mastectomy in our institution.
Results
We analyzed 100 CPMs: 51% (n = 51) had bilateral breast MRI before CPM, 54% (n = 54) had genetic testing prior to CPM, and 56% (n = 30) had a deleterious genetic result. Another 12% (n = 12) had lobular histology as the primary determinant for CPM. Of patients without genetic mutation or lobular histology, 13% (n = 13) had suspicious MRI findings in the CPM side that drove the decision for CPM. Forty-seven percent (n = 47) had reconstructive surgery documented.
Conclusion
Only 42% (n = 42) of patients who underwent CPM had a documented justifiable medical reason. In the future, physician and patient education may decrease unindicated CPM. We also found that 13% of women without a medical indication chose CPM based on suspicious MRI findings, while only 8% of these MRI findings were malignant.
Level of Evidence IV
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tuttle TM, Barrio AV, Klimberg MD et al (2017) Guidelines for guidelines: an assessment of the American society of breast surgeons contralateral prophylactic mastectomy consensus statement. Ann Surg Oncol 24(1):1–2
Parker PA, Peterson SK, Bedrosian I et al (2016) Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg 263(1):178–183
Montgomery LL, Tran KN, Heelan MC et al (1999) Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6(6):546–552
Boughey JC, Attai DJ, Chen SL et al (2016) Contralateral prophylactic mastectomy (CPM) consensus statement from the American society of breast surgeons: data on CPM outcomes and risks. Ann Surg Oncol 23(10):3100–3105
Kruper L, Kauffmann RM, Smith DD, Nelson RA (2014) Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. Ann Surg Oncol 21(11):3448–3456
Hunt KK, Euhus DM, Boughey JC et al (2017) Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol 24(2):375–397
Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcom. Breast Cancer Res 6:R149
Yi M, Meric-Bernstam F, Middleton LP et al (2009) Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962–971
Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base. Ann Surg Oncol 17(10):2554–2562
Guillem JG, Wood WC, Moley JF et al (2006) ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24(28):4642–4660
You YN, Lakhani VT, Wells SA (2007) The role of prophylactic surgery in cancer prevention. World J Surg 31:450–464
Ingrham SL, Sperrin M, Baildam A et al (2013) Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at the time of family referral. Breast Cancer Res Treat 142:611–618
Hartmann LC, Lindor NM (2016) The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 374:454–468
Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209
Sm Rosenberg, Tracy MS, Meyer ME et al (2013) Perceptions, knowledge and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 159(6):373–381
Soran A, Ibrahim A, Kanbour M et al (2015) Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer. Am J Clin Oncol 38(2):179–183
Han E, Johnson N, Glissmeyer M et al (2011) Increasing incidence of bilateral mastectomies: the patient perspective. Am J Surg 201(5):615–618
Fisher CS, Martin-Dunlap T, Ruppel MB et al (2012 ) Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol 19(10):3246–3250
Chen Z, Kolor K, Grosse SD et al (2018) Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003-2014. Genet Med. 20(4):428–434
Guo F, Hirth JM, Lin YL et al (2017) Use of BRCA mutation test in the U.S., 2004–2014. Am J Prev Med. 52(6):702–709
Roberts MC, Dusetzina SB (2017) The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. J Community Genet. 8(2):141–146
Felix GES, Zheng Y, Olopade OI (2018) Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer 17(4):471–483
Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371:497–506
Couch FJ, Shimelis H, Hu C et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 3(9):1190–1196
Sim Y, Tan VK, Ho GH et al (2014) Contralateral prophylactic mastectomy in an Asian population: a single institution review. Breast 23(1):56–62
Wong SM, Freedman RA, Sagara Y et al (2017) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265(3):581–589
Frost MH, Slezak JM, Tran NV et al (2005) Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 23(31):7849–7856
Qin Q, Tan Q, Lian B, Mo Q, Huang Z, Wei C (2018) Postoperative outcomes of breast reconstruction after mastectomy: a retrospective study. Medicine (Baltimore). 97(5):e9766
Cabanuz A, Del Amo A, Barles N, Sanchez G (2018) Influence of radiotherapy on immediate breast reconstruction after skin-sparking mastectomy. Before or after: does it matter? Cir Esp. 97(3):156–161
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
For this type of study, formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Fairbairn, K., Cervantes, A., Rayhrer, C. et al. Trends in Contralateral Prophylactic Mastectomy. Aesth Plast Surg 44, 323–329 (2020). https://doi.org/10.1007/s00266-019-01582-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00266-019-01582-4